IRIS
GRAZIANI, GRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 86.705
EU - Europa 9.985
AS - Asia 9.756
SA - Sud America 1.221
Continente sconosciuto - Info sul continente non disponibili 603
AF - Africa 130
OC - Oceania 37
Totale 108.437
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 86.244
SG - Singapore 5.094
IT - Italia 2.855
CN - Cina 1.947
DE - Germania 1.227
UA - Ucraina 1.164
RU - Federazione Russa 1.008
BR - Brasile 987
FR - Francia 781
IE - Irlanda 749
HK - Hong Kong 692
VN - Vietnam 592
GB - Regno Unito 463
FI - Finlandia 454
SE - Svezia 444
PL - Polonia 366
KR - Corea 308
JP - Giappone 301
CA - Canada 238
BD - Bangladesh 205
NL - Olanda 171
IN - India 129
MX - Messico 95
ID - Indonesia 91
AR - Argentina 79
CO - Colombia 56
TR - Turchia 53
AT - Austria 50
ES - Italia 48
ZA - Sudafrica 44
IQ - Iraq 41
CZ - Repubblica Ceca 39
PH - Filippine 36
JM - Giamaica 35
VE - Venezuela 33
AU - Australia 31
IR - Iran 29
BE - Belgio 28
PK - Pakistan 27
AL - Albania 26
EC - Ecuador 25
MY - Malesia 21
EG - Egitto 20
CR - Costa Rica 19
LT - Lituania 19
MA - Marocco 19
UZ - Uzbekistan 18
IL - Israele 17
AE - Emirati Arabi Uniti 16
CL - Cile 16
KG - Kirghizistan 16
SA - Arabia Saudita 16
CH - Svizzera 15
EU - Europa 12
HN - Honduras 12
KE - Kenya 12
PE - Perù 12
TH - Thailandia 12
BG - Bulgaria 11
KZ - Kazakistan 11
TW - Taiwan 11
JO - Giordania 10
TT - Trinidad e Tobago 10
EE - Estonia 9
GT - Guatemala 9
TN - Tunisia 9
DO - Repubblica Dominicana 8
NI - Nicaragua 8
NP - Nepal 8
PT - Portogallo 8
BH - Bahrain 7
DK - Danimarca 7
NG - Nigeria 7
AZ - Azerbaigian 6
PS - Palestinian Territory 6
PY - Paraguay 6
RO - Romania 6
BS - Bahamas 5
GE - Georgia 5
GR - Grecia 5
HU - Ungheria 5
LB - Libano 5
MK - Macedonia 5
OM - Oman 5
SY - Repubblica araba siriana 5
UY - Uruguay 5
BB - Barbados 4
DZ - Algeria 4
KH - Cambogia 4
NZ - Nuova Zelanda 4
PA - Panama 4
PR - Porto Rico 4
SI - Slovenia 4
SV - El Salvador 4
CY - Cipro 3
LU - Lussemburgo 3
RS - Serbia 3
AG - Antigua e Barbuda 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
Totale 107.806
Salva come PNG Salva come JPEG
Città #
Woodbridge 24.334
Houston 19.914
Wilmington 19.898
Ashburn 2.566
Singapore 2.126
Ann Arbor 2.050
Fairfield 1.618
San Jose 1.210
Chandler 1.044
Jacksonville 1.021
Beijing 708
Dublin 691
Hong Kong 678
Seattle 657
New York 584
Cambridge 550
Council Bluffs 533
Medford 533
Rome 483
Dearborn 451
Santa Clara 374
The Dalles 318
Kraków 301
Dallas 292
Los Angeles 290
Lawrence 255
Tokyo 233
Helsinki 204
Milan 204
Ho Chi Minh City 180
Mülheim 176
Buffalo 164
Moscow 147
Hanoi 134
Menlo Park 127
Lauterbourg 112
São Paulo 110
Atlanta 106
Zhengzhou 97
Boardman 95
San Diego 94
Chicago 87
Phoenix 80
Denver 64
Toronto 64
Nuremberg 62
Guangzhou 59
Mountain View 56
Brooklyn 54
London 54
Redwood City 54
University Park 53
North Bergen 52
Jakarta 50
Falls Church 48
Naples 47
Frankfurt am Main 45
Columbus 44
Munich 43
San Francisco 43
Shanghai 42
Nanjing 41
Norwalk 41
Hefei 40
Orem 40
Palo Alto 40
Philadelphia 40
Florence 37
San Mateo 37
Warsaw 36
Redondo Beach 33
Verona 32
Boston 31
Montreal 31
Rio de Janeiro 31
Hangzhou 30
Xi'an 29
Catania 27
Johannesburg 27
Brussels 26
Civitavecchia 26
Seoul 25
Belo Horizonte 24
Stockholm 24
Ottawa 23
Prague 23
Kunming 22
Mexico City 22
Pisa 22
Salt Lake City 22
Turin 21
Washington 21
Bari 20
Campinas 20
Engelhard 20
Kingston 20
Miami 20
Saint Petersburg 20
Baghdad 19
Kansas City 19
Totale 87.845
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 1.617
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. 880
Parte V- Farmaci per il trattamento di infezioni, tumori e malattie immunologiche; Capitoli: 49, Principi di chemioterapia antimicrobica; 50, Farmaci antibatterici; 51, Farmaci antivirali; 52, Farmaci antifungini; 53, Farmaci antiprotozoari; 54, Farmaci anti-elmintici; 55, Farmaci antitumorali. Farmacologia, VII edizione Italiana di Rang and Dale's Pharmacology (VII ed. Inglese); p.616-680. 693
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 661
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 622
Influence of bacillus calmette-guerin (BCG) on induction of antigen-presenting cd1b molecule by granulocyte- macrophage colony stimulating factor (GM-CSF). 612
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 572
Chimeric molecules between keratinocyte growth factor and basic fibroblast growth factor define domains that confer receptor binding specificities 560
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 556
Differential profile of NK target structures (NKTS) of mouse fibroblasts and lymphoma cells 554
Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells 548
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report 547
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 545
Requirement of phospholipase C-catalyzed hydrolysis of phosphatidylcholine for maturation of Xenopus laevis oocytes in response to insulin and ras p21 541
VIII edizione Rang & Dale's Pharmacology, edizione italiana Rang & Dale Farmacologia Edra LSWR Edizioni 9788821440397. 526
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 525
Targeted therapy for brain tumours: role of PARP inhibitors 519
BCG-infected adherent mononuclear cells release cytokines that regulate group 1 CD1 molecule expression 515
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 512
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells 510
INVECCHIAMENTO, IMMUNITÀ E FARMACI 510
Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha 509
Bacillus Calmette-Guerin down-regulates CD1b induction by granulocyte-macrophage colony stimulating factor in human peripheral blood monocytes 509
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome 502
Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence 502
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 501
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 499
5(2-bromovinyl)-2’-deoxyuridine (BVDU), increases the amount of chromatid breaks induced by bleomycin in mismatch repair deficient tumor cells by inhibiting homologous recombination 498
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 497
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 495
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 494
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 494
New aspects of immune responses against mycobacteria: immunopharmacology studies 494
Traduzione e revisione capitoli di 38, 39, 40, 43, 48 e 56 della 10a edizione 2007 Inglese Basic and Clinical Pharmacology McGraw-Hill - Katzung corrispondente alla 7a edizione 2009 Italiana Piccin 491
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 490
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro 490
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 489
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 487
Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells 486
I FARMACI E LA FRAGILITA’ 486
Challenging resistance mechanisms to therapies for metastatic melanoma 485
Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes 482
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 482
Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid 481
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds 480
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 479
Trattato di Medicina Interna Gasbarrini G. Volume 3 479
Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV) 479
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 475
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 474
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 474
Pharmacological strategies to increase the antitumor activity of methylating agents 474
Immunopharmacology of antitumor agents. 474
Exploiting Microglial Functions for the Treatment of Glioblastoma 473
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 469
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells 468
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 468
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 467
In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype 467
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 467
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 467
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 466
Emergence of double-positive CD4/CD8 cells from adult peripheral blood mononuclear cells infected with human T cell leukemia virus type I (HTLV-I) 466
Antigenic changes induced in tumor cells in vivo by dimethil-imidazole carboxamide (DTIC) 465
NF-kB is activated in response to temozolomide and confers protection against drug-induced cell growth inhibition 464
In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers 463
Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine 462
Modulation of GDF11 expression and synaptic plasticity by age and training 462
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 460
Capitoli 37, 38, 39, 55 di Farmacologia IX Ed. Italiana di Katzung B.G. Masters S.B. Trevor A.J. (XII Ed. Americana) 460
Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro 459
Clinical perspectives of PARP inhibitors 458
Role of GTPase activating protein in mitogenic signalling through phosphatidylcholine-hydrolysing phospholipase C 458
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 458
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 457
Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line 454
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 454
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 452
Valproic acid inhibits proliferation and affects androgen sensitività in prostatic cancer cells 452
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 451
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 451
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding 451
Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells 450
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 450
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 450
Soluble factor(s) are responsible for the influence of BCG on CD1b induction by GM-CSF: studies with recombinant BCG carrying the GFP gene. 450
A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint cluster gene, bcr 450
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 450
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 449
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 448
Activity against melanoma of an anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody that does not hamper ligand binding 448
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 447
5-Fluorouracil increases carcinoembryonic antigen expression and shedding in colon cancer cell clones with different basal levels of the molecule 447
Parte V- Farmaci per il trattamento di infezioni, tumori e malattie immunologiche (capitoli 49, 50, 51, 52, 53, 54, 55) Farmacologia VII edizione Italiana di Rang and Dale's Pharmacology (VII ed. Inglese). p. 616-680. 447
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 447
Role of DNA repair pathways in the control of common fragile sites expression. 446
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 445
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro 445
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 445
Neuropilin-1 as Therapeutic Target for Malignant Melanoma. 444
Totale 50.183
Salva come PNG Salva come JPEG
Categoria #
all - tutte 233.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 233.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.906 0 0 0 131 67 201 143 135 204 174 120 731
2022/20233.220 331 188 77 401 262 759 271 206 296 48 270 111
2023/20241.826 168 41 94 90 146 590 146 77 61 55 104 254
2024/20257.332 235 1.362 659 357 244 495 289 394 711 379 1.190 1.017
2025/202611.152 768 465 1.317 707 939 385 1.193 1.516 1.354 983 909 616
2026/20274.860 722 689 2.235 1.214 0 0 0 0 0 0 0 0
Totale 108.437